Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

ClinicalTrials.gov ID: NCT03015532

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03015532. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 Via Infiltration for Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2b, randomized, double-blind, saline placebo- and active-controlled, multicenter study in subjects undergoing primary unilateral total knee arthroplasty (TKA) to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 administered via infiltration to the surgical site.

Study identification

NCT ID: NCT03015532
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Heron Therapeutics; Industry
Enrollment: 285 participants

Conditions and interventions

Conditions

Postoperative Pain

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 13, 2017 (Actual)
Primary completion: Apr 20, 2018 (Actual)
Completion: May 16, 2018 (Actual)
Last update posted: Mar 2, 2026

2017 – 2018

United States locations

U.S. sites: 24
U.S. states: 7
U.S. cities: 16

Facility	City	State	ZIP	Site status
Not listed	Mobile	Alabama	36608	—
Not listed	Sheffield	Alabama	35660	—
Not listed	Phoenix	Arizona	85015	—
Not listed	Phoenix	Arizona	85023	—
Not listed	La Jolla	California	92037	—
Not listed	Riverside	California	92503	—
Not listed	San Diego	California	92103	—
Not listed	Miami	Florida	33136	—
Not listed	Miami	Florida	33143	—
Not listed	Miami	Florida	33155	—
Not listed	Tamarac	Florida	33321	—
Not listed	Las Vegas	Nevada	89109	—
Not listed	Columbus	Ohio	43203	—
Not listed	Columbus	Ohio	43210	—
Not listed	Dayton	Ohio	45417	—
Not listed	Bellaire	Texas	77401	—
Not listed	Houston	Texas	77004	—
Not listed	Houston	Texas	77027	—
Not listed	Houston	Texas	77043	—
Not listed	Plano	Texas	75093	—
Not listed	San Antonio	Texas	78209	—
Not listed	San Antonio	Texas	78229	—
Not listed	San Antonio	Texas	78240	—
Not listed	Webster	Texas	77598	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03015532, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 2, 2026 · Synced Nov 13, 2026